Tonglu Qiu

Nanjing, 210000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Real world outcomes and prognostic factors in Chinese patients with primary mediastinal B cell lymphoma: A single center experience and the Surveillance, Epidemiology, and End Results validation.

Real world outcomes and prognostic factors in Chinese patients with primary mediastinal B cell lymphoma: A single center experience and the Surveillance, Epidemiology, and End Results validation.

Journal: Annals of hematology

Published: December 14, 2025

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Journal: Journal of the National Cancer Center

Published: September 08, 2025

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Journal: Blood advances

Published: May 07, 2025

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Journal: The oncologist

Published: April 01, 2025

Histiocytic necrotizing lymphadenitis with hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 5 cases.

Histiocytic necrotizing lymphadenitis with hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 5 cases.

Journal: Immunity, inflammation and disease

Published: December 26, 2023

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.

Journal: Annals of hematology

Published: August 20, 2023

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Journal: Blood cancer journal

Published: May 03, 2023

The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.

The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.

Journal: Journal of clinical immunology

Published: February 12, 2023

Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases.

Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases.

Journal: Frontiers in immunology

Published: June 15, 2022

DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.

DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.

Journal: Pathology, research and practice

Published: February 28, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026